Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele

The contribution of the tumor microenvironment to the development of pancreatic adenocarcinoma (PDAC) is unclear. The LSL-KrasG12D/+;LSL-p53R172H/+;Pdx-1-Cre (KPC) tumor model, which is widely utilized to faithfully recapitulate human pancreatic cancer, depends on Cre-mediated recombination in the epithelial lineage to drive tumorigenesis. Therefore, specific Cre-loxP recombination in stromal cells cannot be applied in this model, limiting the in vivo investigation of stromal genetics in tumor initiation and progression. To address this issue, we generated a new Pdx1FlpO knock-in mouse line, which represents the first mouse model to physiologically express FlpO recombinase in pancreatic epithelial cells. This mouse specifically recombines Frt loci in pancreatic epithelial cells, including acinar, ductal, and islet cells. When combined with the Frt-STOP-Frt KrasG12D and p53Frt mouse lines, simultaneous Pdx1FlpO activation of mutant Kras and deletion of p53 results in the spectrum of pathologic changes seen in PDAC, including PanIN lesions and ductal carcinoma. Combination of this KPF mouse model with any stroma-specific Cre can be used to conditionally modify target genes of interest. This will provide an excellent in vivo tool to study the roles of genes in different cell types and multiple cell compartments within the pancreatic tumor microenvironment.

[1]  Christian Veltkamp,et al.  A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer , 2014, Nature Medicine.

[2]  Jianmin Wu,et al.  Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling , 2014, Cell.

[3]  M. Barbacid,et al.  Genetically engineered mouse models of pancreatic adenocarcinoma , 2013, Molecular oncology.

[4]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[5]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[6]  M. Barbacid,et al.  What we have learned about pancreatic cancer from mouse models. , 2012, Gastroenterology.

[7]  C. Wright,et al.  A recombinase‐mediated cassette exchange‐derived cyan fluorescent protein reporter allele for Pdx1 , 2012, Genesis.

[8]  James J. Lee,et al.  The construction of transgenic and gene knockout/knockin mouse models of human disease , 2012, Transgenic Research.

[9]  E. Moding,et al.  Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice , 2011, Disease Models & Mechanisms.

[10]  P. Mazur,et al.  Identification of Epidermal Pdx1 Expression Discloses Different Roles of Notch1 and Notch2 in Murine KrasG12D-Induced Skin Carcinogenesis In Vivo , 2010, PloS one.

[11]  Ronald Naumann,et al.  An improved Flp deleter mouse in C57Bl/6 based on Flpo recombinase , 2010, Genesis.

[12]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[13]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[14]  E. Stanley,et al.  Retinoic acid induces Pdx1-positive endoderm in differentiating mouse embryonic stem cells. , 2005, Diabetes.

[15]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[16]  D. Melton,et al.  Genes, signals, and lineages in pancreas development. , 2003, Annual review of cell and developmental biology.

[17]  C. Wright,et al.  Regulatory regions driving developmental and tissue-specific expression of the essential pancreatic gene pdx1. , 2001, Developmental biology.

[18]  C. Wright,et al.  Mosaic Cre‐mediated recombination in pancreas using the pdx‐1 enhancer/promoter , 2000, Genesis.

[19]  H. Edlund,et al.  beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. , 1998, Genes & development.

[20]  H. Schweizer,et al.  A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. , 1998, Gene.

[21]  H. Edlund,et al.  The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. , 1996, Development.

[22]  H. Ohlsson,et al.  IPF1, a homeodomain‐containing transactivator of the insulin gene. , 1993, The EMBO journal.

[23]  H. Friess,et al.  p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. , 1993, Cancer letters.

[24]  A. Malek.  Experimental Metastasis: Modeling and Analysis , 2013, Springer Netherlands.

[25]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[26]  E. Stanley,et al.  Retinoic Acid Induces Pdx 1-Positive Endoderm in Differentiating Mouse Embryonic Stem Cells , 2005 .

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.